Deep venous stents

Abre™ venous self-expanding stent system

The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease.

Ordering information
Contact a representative

Features

Simplicity for you. 
Durability for them.

Watch the Abre™ stent mechanism of action.

Indications

The Abre™ stent system is intended for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.

Clinical evidence

Clinically meaningful impact on quality of life through 36 months — in even the most complex patients.

36-month primary patency†,1:

  • 81.6%  overall
  • 97.1%  NIVL
  • 76.5%  aDVT
  • 70.4%  PT
View full evidence

Product details

Simplicity for you1,2

Hear it from the expert.

Easy deployment to let you focus on your patient.1,2

The Abre™ delivery system is designed for simplicity and the rotating thumbwheel offers auditory feedback.

The Abre™ stent minimizes jumping and foreshortening, landing precisely where you need it.2

Rotating thumbwheel offers predictable placement and auditory feedback.2

The Abre™ delivery system is designed for simplicity and the triaxial shaft design increases stability during deployment.
  1. Isolation sheath
  2. Hemostatic valve
  3. Introducer sheath
  4. Retractable sheath
  5. Inner shaft

Durability for them.1,2

Hear it from the expert.

Demonstrated endurance to give your patients freedom of movement.1,2

The nitinol Abre™ stent maintains lumen integrity and flow in diverse patients and anatomies.1 It ensures radial strength and crush resistance, without compromising flexibility.2

Unique technology:

  • Open-cell design with three offset connection points
  • Struts customized to each size

Consistent behavior across a broad range of diameters and lengths.2

A young woman stretches her legs on a grassy hill.

Bench evidence shows long-term durability.2 Clinical evidence shows real-world dependability, even in challenging cases.1

  • 0% fracture rate in clinical trial with 44% of stents extending below inguinal ligament into the CFV‡,1
  • 0% migration rate in clinical trial1

Ordering information

Item number guide
Stent diameter (mm) Stent length (mm)
40 60 80 100 120 150
10 AB9U10040090 AB9U10060090 AB9U10080090 AB9U10100090 AB9U10120090 AB9U10150090
12 — AB9U12060090 AB9U12080090 AB9U12100090 AB9U12120090 AB9U12150090
14 — AB9U14060090 AB9U14080090 AB9U14100090 AB9U14120090 AB9U14150090
16 — AB9U16060090 AB9U16080090 AB9U16100090 AB9U16120090 AB9U16150090
18 — AB9U18060090 AB9U18080090 AB9U18100090 AB9U18120090 AB9U18150090
20 — AB9U20060090 AB9U20080090 AB9U20100090 AB9U20120090 AB9U20150090

Related links

† Primary patency was defined as meeting all of the following: freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization. 

‡ Site and core lab data were used.

  1. Abre™ venous stent instructions for use.
  2. Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.